ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design...

|About: ARCA biopharma, Inc. (ABIO)|By:, SA News Editor

ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design clinical trial for its lead developmental drug, Gencaro, in atrial fibrillation. Medtronic (MDT) will be collaborating on the initial, phase 2B portion of the proposed trial.